Zhejiang Medicine subsidiary passes US FDA inspection

Zhejiang Medicine (SSE:600216) announced that its subsidiary, Xinchang Pharmaceutical Factory, successfully passed a CGMP (Current Good Manufacturing Practice) inspection by the US Food and Drug Administration (FDA) from March 4th to March 7th, 2025. The inspection covered the quality systems, materials, production, and laboratory controls for oral solid dosage forms and active pharmaceutical ingredients (APIs). The FDA has confirmed that the inspection is closed.